Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Phase III Clinical Trial Evaluating DCVax«-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme.

 


A Phase III Clinical Trial Evaluating DCVax«-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme.


Trial Focus

Brain and Nervous System Tumors

Objective

         The purpose of this study is to see if an investigational agent known as DCVax-Brain can slow the growth and recurrence of your brain tumor and whether it can extend overall survival. Other goals are to test the safety and activity of DCVax-Brain and to

IRB Protocol #

11-1777

Trial Status

OPEN

Principle Investigator

KEVIN LILLEHEI

Sponsor

Northwest Biotherapeutics

Contact

MONICA ROBISCHON at (720) 848-0661 or MONICA.ROBISCHON@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : Following a screening period to determine your eligibility, the active treatment phase lasts up to 36 months and begins after recovery from surgery, radiation therapy and chemotherapy. The follow-up phase starts after the 36 months is completed or after you leave the study for any reason. During the follow-up phase you and/or a designated contact will be contacted every third month to ask how you are doing for the rest of your life. // Eligibility criteria include but are not limited to: persons 18 years and older with Glioblastoma Multiforme.Eligibility criteria include but are not limited to: persons 18 years and older with Glioblastoma Multiforme.